

IOLANTHE

A Phase IV Trial To Confirm The Efficacy Of Olaparib In Combination With Bevacizumab As Maintenance Frontline Treatment Of HRD Positive Ovarian Tumours

Contatti: fborella@cittadellasalute.to.it

Prospective, phase IV, multicenter

Primary endpoints: define proportion and characteristics of HRD test-positive patients treated with olaparib + bevacizumab; efficacy in terms of 24-month PFS; translational research

Study Drug Key: Bevacizumab + Olaparib according to clinical practice

Eligibility Criteri:

- Patients with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer at surgery or at diagnostic biopsy and fulfilling the eligibility criteria to start CHT in association with bevacizumab
- Informed consent before biopsy or PDS
- HRD-positive tumor according to the Myriad Mychoice CDx Plus evaluation (central review of FFPE samples).